atorvastatin has been researched along with Cardiac Failure in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 38 (40.43) | 29.6817 |
| 2010's | 48 (51.06) | 24.3611 |
| 2020's | 8 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Panasenko, M; Samura, B | 1 |
| Abramson, JS; Armand, P; Asnani, A; Barnes, JA; Brahmbhatt, P; Drobni, ZD; Friedman, RS; Gilman, HK; Han, Y; Heemelaar, JC; Ho, JS; Hochberg, EP; Hua, L; Jacobsen, ED; Jacobson, CA; Januzzi, JL; Jerosch-Herold, M; Kim, AI; Kwong, RY; Ky, B; Lacasce, AS; Landsburg, D; Mahmood, SS; Mousavi, N; Nasta, S; Neilan, TG; Neuberg, DS; Onoue, T; Quinaglia, T; Redd, RA; Sama, S; Scherrer-Crosbie, M; Smith, A; Soumerai, JD; Svoboda, J | 1 |
| Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI | 1 |
| Czitrom, D; Ennezat, PV; Le Jemtel, TH; Malergue, MC; Maréchaux, S; Tricot, O; Vincentelli, A | 1 |
| Liang, Z; Ma, T; Sun, D; Zhang, F; Zhang, Y | 1 |
| Desai, RJ; Imran, T; Schneeweiss, S; Wong, A | 1 |
| Bai, L; Cui, XR; Wang, D; Yang, XH; Zhang, JD | 1 |
| Bolek, T; Galajda, P; Kubisz, P; Mokáň, M; Samoš, M; Škorňová, I; Stančiaková, L; Staško, J; Vádelová, Ľ | 1 |
| Begić, E; Dilić, M; Lepara, O; Sokolović, Š; Zvizdić, F | 1 |
| Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD | 1 |
| Carroll, C; Hassanin, A | 1 |
| Huang, J; Li, HH; Liang, FL; Mo, JL; Ou, BQ; Peng, Y; Zhou, Z | 1 |
| Furusho, H; Hamaoka, T; Inoue, O; Kaneko, S; Kato, T; Mukai, Y; Murai, H; Okabe, Y; Sugimoto, H; Takamura, M; Takashima, SI; Tokuhisa, H; Usui, S | 1 |
| Chen, W; Gao, G; Ge, L; Jiang, S; Sui, S; Zhai, C; Zhang, S | 1 |
| Cui, W; Hu, HJ; Liu, DM; Liu, J; Wang, Q; Zhang, HL; Zhang, YN | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR | 1 |
| Andalib, S; Garjani, A; Khorrami, A; Maleki-Dijazi, N; Shayanfar, A | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Chen, W; Gao, DC; Ye, PX; Ye, PZ; Zhu, JH | 1 |
| Choi, D; Hong, N; Kang, SM; Lee, SH; Oh, J; Park, S; Youn, JC | 1 |
| Akiyama, E; Kimura, K; Kosuge, M | 1 |
| Qu, Y; Wei, L; Zhang, H | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Athanasiou, D; Chrysohoou, C; Hatzis, G; Mazaris, S; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Zaromitidou, M; Zisimos, K | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Berg, AH; Drechsler, C; Hod, T; Kalim, S; Karumanchi, SA; Suntharalingam, P; Thadhani, RI; Wanner, C; Wenger, JB | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Ferraretti, A; Monaco, I; Passero, T; Totaro, A | 1 |
| Raj, DS; Ramezani, A; Velasquez, MT | 1 |
| An, LP; An, SK; Fu, SY; Wei, XH; Wu, HA | 1 |
| Chu, YJ; Duan, HY; Fan, XW; Liu, DM; Qian, P; Wang, SL; Wu, JT; Yan, LJ; Yang, HT | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Chen, ZC; Cheng, KL; Cheng, SY; Guo, YZ; Ou, MD; Wang, Q; Xue, JJ; Zeng, WJ; Zhang, YT | 1 |
| Cooper, LS; Dunning, A; Fiuzat, M; Fleg, JL; Kelly, JP; Keteyian, SJ; Kitzman, DW; Kraus, WE; Leifer, ES; Mentz, RJ; O'Connor, CM; Pina, IL; Schulte, PJ; Whellan, DJ | 1 |
| Braunwald, E; Cannon, CP; Daga, S; Dalby, AJ; Eisen, A; Goodrich, EL; Im, K; Lukas, MA; O'Donoghue, ML; Spinar, J; Steen, DL; Zhou, J | 1 |
| Deedwania, P; Singh, V | 1 |
| Ford, JS; Tayek, JA | 1 |
| Martin, J | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Assmann, G; Breithardt, G; Nofer, JR; Schubert, A; Schulte, H; Stypmann, J; Welp, H | 1 |
| von Haehling, S | 1 |
| Cui, W; Liu, F; Lu, JC; Pei, WN; Xie, RQ; Yang, C | 1 |
| Kotyla, PJ | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Kishi, T; Okamatsu, S; Sunagawa, K; Yamada, A | 1 |
| Anker, SD; Földes, G; von Haehling, S | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK | 1 |
| Strandberg, TE | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Funder, JW | 1 |
| Ducharme, A; Dupuis, J; Jiang, BH; Martin, JG; Sauvageau, S; Shi, Y; Tardif, JC | 1 |
| Alcaino, H; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; López, R; Mellado, R; Navarro, M; Nogerol, C; Tapia, F; Verdejo, HE | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Korkor, MT; Liu, B; Liu, JY; Song, XJ; Wei, Q; Yang, CY; Yang, P | 1 |
| Fonarow, GC; Horwich, TB; Maclellan, WR; Middlekauff, HR | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Takagi, H; Umemoto, T | 1 |
| Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Mizuno, K; Shinada, T; Shirakabe, A; Tomita, K; Tsurumi, M; Yokoyama, S | 1 |
| Breazna, A; Deedwania, PC; Demicco, DA; Ho, JE; Kean, A; Khush, KK; Waters, DD; Wilson, DJ; Wun, CC | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Doevendans, PA; Goumans, MJ; Pasterkamp, G; Post, S; Rensing, BJ; van den Broek, AJ | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
| Böhm, M; Fries, R | 1 |
| Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Trikas, A; Tsioufis, C | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Panagiotakos, D; Pitsavos, C; Stefanadis, C; Tousoulis, D; Vlachopoulos, C | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM | 1 |
| Antoniades, C; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Toutouza, M; Trikas, A; Vassiliadou, C | 1 |
| van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Hamaad, A; Lip, GY; MacFadyen, RJ; Sosin, M | 1 |
| Lawler, RL; Letterer, RA; Levy, WC; McDonald, GB; Minami, E; Mozaffarian, D | 1 |
| Esberg, D; Kowey, P | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Starc, V; Vrtovec, B | 1 |
| Khan, BV; Lerakis, S; Mir, MQ; Sola, S; Tandon, N | 1 |
| Badziński, A; Dyrbuś, K; Mercik, G; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Rozek, MM; Szyguła-Jurkiewicz, B; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M | 1 |
| Frampton, CM; Lainchbury, JH; Nicholls, MG; Richards, AM; Scott, RS; Strey, CH; Young, JM | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Loh, PH; Tin, L | 1 |
| Gong, K; Song, G; Zhang, Z | 1 |
| Bittner, V; Deedwania, PC; Kastelein, JJ; Khush, KK; Lewis, SJ; Waters, DD; Wenger, NK | 1 |
| Bao, XF; Cai, HW; Cheng, G; Wang, HH; Xu, G | 1 |
| Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Khaleva, O | 1 |
| Horwich, TB; MacLellan, WR | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Schlegel, TT; Starc, V; Vrtovec, B | 1 |
| Asakura, M; Asanuma, H; Kato, H; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Ogai, A; Takashima, S; Zhao, H | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
12 review(s) available for atorvastatin and Cardiac Failure
| Article | Year |
|---|---|
[Benefit of elective percutaneous coronary intervention for stable coronary artery disease].
Topics: Age Factors; Angina Pectoris; Atorvastatin; Coronary Artery Disease; Diabetic Angiopathies; Elective Surgical Procedures; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Meta-Analysis as Topic; Percutaneous Coronary Intervention; Placebo Effect; Randomized Controlled Trials as Topic; Reoperation; Stents; Surgical Procedures, Operative; Treatment Outcome | 2019 |
Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies.
Topics: Atorvastatin; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MEDLINE; Prospective Studies; Pyrroles | 2014 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
Statins and congestive heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2008 |
Statins for heart failure: still caught in no man's land?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Evidence-Based Medicine; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Pyrroles | 2009 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Topics: Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke Volume; Sulfonamides | 2012 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Atorvastatin and statins in the treatment of heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Agents; Drug Interactions; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Pyrroles; Treatment Outcome | 2007 |
38 trial(s) available for atorvastatin and Cardiac Failure
| Article | Year |
|---|---|
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Cardiovascular Agents; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Heart Failure; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2023 |
Effectiveness of Atorvastatin in the Treatment of Asymptomatic Heart Failure After Myocardial Infarction: A Clinical Study.
Topics: Atorvastatin; Heart Failure; Humans; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2020 |
Differential effects of lipophilic and hydrophilic statins on muscle sympathetic nerve activity in heart failure with preserved left ventricular ejection fraction.
Topics: Atorvastatin; Baroreflex; Blood Pressure; Cross-Over Studies; Female; Heart Failure; Heart Rate; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Muscles; Rosuvastatin Calcium; Solubility; Sympathetic Nervous System; Ventricular Function, Left | 2018 |
[Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension].
Topics: Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Endothelins; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles | 2014 |
Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Randomized, controlled, open-label, prospective pilot study.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Female; Heart Failure; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Prospective Studies; Pyrroles | 2014 |
Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Coronary Artery Disease; Disease-Free Survival; Drug Administration Schedule; Emergencies; Female; Heart Failure; Hospitalization; Humans; Incidence; Inflammation Mediators; Interleukin-6; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prospective Studies; Risk Factors; Single-Blind Method; Surgical Procedures, Operative; Time Factors; Treatment Outcome | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Atorvastatin; Biomarkers; Brachial Artery; Cell Movement; Cross-Over Studies; Double-Blind Method; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Glycoproteins; Greece; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Peptides; Pyrroles; Recovery of Function; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor Receptor-2; Vasodilation | 2015 |
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Cause of Death; Cholesterol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Renal Dialysis; Risk Factors; Serum Albumin; Survival Rate; Troponin T; Uremia | 2015 |
Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION.
Topics: Aged; Atorvastatin; Exercise Therapy; Exercise Tolerance; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Oxygen Consumption; Pravastatin; Quality of Life; Simvastatin; Stroke Volume; Treatment Outcome; Walk Test | 2016 |
Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure.
Topics: Atorvastatin; Echocardiography; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Protein Precursors; Pyrroles; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2008 |
Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Electrocardiography; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long QT Syndrome; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2010 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
Topics: Allopurinol; Atorvastatin; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Pyrroles; Regional Blood Flow; Treatment Outcome; Xanthine Oxidase | 2011 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peroneal Nerve; Pyrroles; Stroke Volume; Surveys and Questionnaires; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 2; Prognosis; Pyrroles; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies | 2012 |
Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Glomerular Filtration Rate; Greece; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Incidence; Male; Prognosis; Pyrroles; Reference Values; Survival Rate; Treatment Outcome | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Endothelium, Vascular; Fibrinolysis; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Lipids; Middle Aged; Pyrroles; Regional Blood Flow; Vasodilation | 2005 |
Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cytokines; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Inflammation; Male; Middle Aged; Pyrroles; Regional Blood Flow; Vascular Cell Adhesion Molecule-1 | 2005 |
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Coenzymes; Cross-Over Studies; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Vascular Resistance; Vasodilation | 2005 |
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
Topics: Aged; Antioxidants; Atorvastatin; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vasodilation; Vitamin E | 2005 |
Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure.
Topics: Adult; Aged; Atorvastatin; Autonomic Nervous System; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Single-Blind Method; Systole | 2005 |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
Topics: Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Receptors, Tumor Necrosis Factor, Type I; Treatment Outcome | 2005 |
Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Electrocardiography; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Pyrroles; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
Topics: Atorvastatin; C-Reactive Protein; Double-Blind Method; Erythrocytes; Female; Heart Failure; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Pilot Projects; Pyrroles; Receptors, Tumor Necrosis Factor, Type II; Stroke Volume; Superoxide Dismutase; Systole; Ultrasonography; Ventricular Function, Left | 2006 |
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
Topics: Adult; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol, LDL; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Myocardium; Pyrroles; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2006 |
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.
Topics: Atorvastatin; Biomarkers; Cholesterol; Cross-Over Studies; Double-Blind Method; Echocardiography; Endothelium, Vascular; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptides; Pyrroles; Vascular Resistance; Vasodilation | 2006 |
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Drug Delivery Systems; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Pyrroles | 2007 |
Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
Topics: Aged; Atorvastatin; Atrial Natriuretic Factor; Disease-Free Survival; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Stroke Volume; Ventricular Dysfunction, Left | 2007 |
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
Topics: Atorvastatin; Death, Sudden, Cardiac; Disease Progression; Female; Health Status Indicators; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Risk Factors; Stroke Volume | 2008 |
Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure.
Topics: Arginine; Atorvastatin; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ventricular Dysfunction, Left | 2008 |
44 other study(ies) available for atorvastatin and Cardiac Failure
| Article | Year |
|---|---|
SST2 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA.
Topics: Atorvastatin; Biomarkers; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Myeloma; Prognosis; Treatment Outcome | 2022 |
[Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?]
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Obesity; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Atorvastatin alleviates left ventricular remodeling in isoproterenol-induced chronic heart failure in rats by regulating the RhoA/Rho kinase signaling pathway.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Chronic Disease; Echocardiography; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Nitric Oxide Synthase Type III; Rats; Rats, Wistar; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; Ventricular Remodeling | 2020 |
Statin Lipophilicity and the Risk of Incident Heart Failure.
Topics: Atorvastatin; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Propensity Score; Rosuvastatin Calcium | 2020 |
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Topics: Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Female; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thrombosis | 2021 |
Effect of atorvastatin on systolic and diastolic function in patients with heart failure with reduced ejection fraction (HFrEF).
Topics: Atorvastatin; Diastole; Heart Failure; Humans; Stroke Volume; Systole | 2021 |
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2017 |
Polypharmacy in the Elderly-When Good Drugs Lead to Bad Outcomes: A Teachable Moment.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Antihypertensive Agents; Atorvastatin; Atrial Fibrillation; Bone Density Conservation Agents; Deprescriptions; Digoxin; Diltiazem; Diuretics; Drug Overdose; Factor Xa Inhibitors; Female; Furosemide; Heart Failure; Histamine H1 Antagonists, Non-Sedating; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Lisinopril; Loratadine; Metoprolol; Polypharmacy; Pyrazoles; Pyridones; Ranitidine; Syncope | 2017 |
Synergistic Effect of Atorvastatin and Folic Acid on Cardiac Function and Ventricular Remodeling in Chronic Heart Failure Patients with Hyperhomocysteinemia.
Topics: Aged; Aged, 80 and over; Atorvastatin; China; Chronic Disease; Female; Folic Acid; Heart Failure; Heart Function Tests; Humans; Hyperhomocysteinemia; Male; Middle Aged; Ventricular Remodeling | 2018 |
Atorvastatin Improves Doxorubicin-Induced Cardiac Dysfunction by Modulating Hsp70, Akt, and MAPK Signaling Pathways.
Topics: Animals; Apoptosis; Atorvastatin; Cardiotoxicity; Caspase 3; Disease Models, Animal; Doxorubicin; Fibrosis; Heart Failure; Heart Ventricles; HSP70 Heat-Shock Proteins; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Chronic Disease; DNA; Fibroblasts; Flow Cytometry; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Atorvastatin reduces the myocardial content of coenzyme Q10 in isoproterenol-induced heart failure in rats.
Topics: Animals; Antioxidants; Atorvastatin; Heart Failure; Heptanoic Acids; Isoproterenol; Lipid Peroxidation; Lipids; Male; Malondialdehyde; Myocardium; Pyrroles; Rats; Rats, Wistar; Ubiquinone | 2014 |
Is high-dose statin loading effective for acute decompensated heart failure? Insight of inflammation and acute kidney injury.
Topics: Acute Kidney Injury; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrroles | 2014 |
Lower cardiovascular mortality with atorvastatin and rosuvastatin vs simvastatin: Data from "moderate-intensity" statin users in an observational registry on chronic heart failure (Daunia Heart Failure Registry).
Topics: Aged; Atorvastatin; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Observational Studies as Topic; Randomized Controlled Trials as Topic; Registries; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Ventricular Function, Left | 2015 |
Urea and protein carbamylation in ESRD: surrogate markers or partners in crime?
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Serum Albumin | 2015 |
Atorvastatin improves cardiac function of rats with chronic cardiac failure via inhibiting Rac1/P47phox/P67phox-mediated ROS release.
Topics: Animals; Atorvastatin; Chronic Disease; Heart Failure; Hemodynamics; Humans; Male; NADH, NADPH Oxidoreductases; NADPH Oxidases; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Reactive Oxygen Species | 2015 |
Effect of atorvastatin on plasma NT-proBNP and inflammatory cytokine expression in patients with heart failure.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cytokines; Echocardiography; Female; Heart Failure; Heart Function Tests; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome | 2015 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
The Effects and Mechanism of Atorvastatin on Pulmonary Hypertension Due to Left Heart Disease.
Topics: Animals; Aorta; Apoptosis; Arterioles; Atorvastatin; Cell Proliferation; Heart Diseases; Heart Failure; Hemodynamics; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inflammation; Lung; Macrophages; Male; Myocardial Ischemia; Neutrophils; Rats; Rats, Sprague-Dawley | 2016 |
Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Atorvastatin; Benzaldehydes; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Oximes; Phospholipase A2 Inhibitors; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Renal Insufficiency; Rosuvastatin Calcium; Secondary Prevention; Sex Factors; Simvastatin | 2017 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Atorvastatin pleiotropic effects mediated via suppression of TNF-alpha in congestive heart failure patients with initial normal TNF-alpha levels.
Topics: Animals; Apoptosis; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrroles; Reference Values; Tumor Necrosis Factor-alpha | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Heart Failure; Heart Ventricles; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrroles; Retrospective Studies; Ventricular Premature Complexes | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Heart Failure; Heptanoic Acids; Humans; Pyrroles; Signal Transduction; Th1 Cells; Th2 Cells | 2009 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure.
Topics: Animals; Atorvastatin; Cells, Cultured; Heart Failure; Heptanoic Acids; Lung; Myocardial Infarction; Myofibroblasts; Pyrroles; Random Allocation; Rats; Respiratory Function Tests | 2010 |
Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Topics: Animals; Atorvastatin; Body Weight; Drug Interactions; Heart Failure; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Myocardium; Organ Size; Pyrroles; Rats; Rats, Wistar; Ubiquinone; Ventricular Dysfunction, Left | 2011 |
Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 12; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Heart Failure; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Myocardial Infarction; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Wistar; Transcription Factor CHOP | 2011 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study.
Topics: Adult; Aged; Atorvastatin; Cell Movement; Chemokine CXCL12; Dipeptidyl Peptidase 4; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Pyrroles | 2012 |
Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Biological Availability; Capillaries; Cells, Cultured; Collateral Circulation; Drug Resistance; Endothelial Cells; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Random Allocation; Ultrasonography; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2004 |
Statins and autonomic function in chronic heart failure.
Topics: Atorvastatin; Autonomic Nervous System; Chronic Disease; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Does "anti-lipid" also mean "anti-arrhythmic"?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.
Topics: Anemia; Atorvastatin; Cardiology; Clinical Trials as Topic; Congresses as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Europe; Exercise Tolerance; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Societies, Medical; Xanthines | 2006 |
Statin therapy for patients with chronic heart failure.
Topics: Atorvastatin; Cholesterol; Diastole; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2006 |
Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase-2 and 9 in rats.
Topics: Animals; Arteriovenous Fistula; Atorvastatin; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ultrasonography | 2007 |
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Topics: Acute Disease; Amides; Atorvastatin; Cardiac Pacing, Artificial; Clinical Trials as Topic; Fumarates; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Edema; Pyrroles; Renin; Respiration, Artificial | 2007 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Topics: Animals; Atorvastatin; Cardiomegaly; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Heart Failure; Heparin-binding EGF-like Growth Factor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation; Pyrroles; Ventricular Function, Left | 2008 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |